FI3730608T3 - Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa - Google Patents
Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa Download PDFInfo
- Publication number
- FI3730608T3 FI3730608T3 FIEP20161179.5T FI20161179T FI3730608T3 FI 3730608 T3 FI3730608 T3 FI 3730608T3 FI 20161179 T FI20161179 T FI 20161179T FI 3730608 T3 FI3730608 T3 FI 3730608T3
- Authority
- FI
- Finland
- Prior art keywords
- tils
- population
- cancer
- cells
- therapeutic
- Prior art date
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title claims 37
- 238000000034 method Methods 0.000 title claims 23
- 238000009169 immunotherapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 6
- 230000035899 viability Effects 0.000 claims 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 238000010257 thawing Methods 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 238000005138 cryopreservation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 102000055501 telomere Human genes 0.000 claims 1
- 108091035539 telomere Proteins 0.000 claims 1
- 210000003411 telomere Anatomy 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478506P | 2017-03-29 | 2017-03-29 | |
| US201762539410P | 2017-07-31 | 2017-07-31 | |
| US201762548306P | 2017-08-21 | 2017-08-21 | |
| US201762554538P | 2017-09-05 | 2017-09-05 | |
| US201762559374P | 2017-09-15 | 2017-09-15 | |
| US201762567121P | 2017-10-02 | 2017-10-02 | |
| US201762577655P | 2017-10-26 | 2017-10-26 | |
| US201762582874P | 2017-11-07 | 2017-11-07 | |
| US201762596374P | 2017-12-08 | 2017-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3730608T3 true FI3730608T3 (fi) | 2024-12-30 |
Family
ID=61569356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20161179.5T FI3730608T3 (fi) | 2017-03-29 | 2018-01-05 | Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa |
| FIEP20161276.9T FI3722415T3 (fi) | 2017-03-29 | 2018-01-05 | Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttöjä immunoterapiassa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20161276.9T FI3722415T3 (fi) | 2017-03-29 | 2018-01-05 | Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttöjä immunoterapiassa |
Country Status (37)
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| US11261428B2 (en) | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| EP3635097A1 (en) * | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| EP4501408A3 (en) * | 2017-11-17 | 2025-04-09 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| US20200299349A1 (en) | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| EP3714041A1 (en) | 2017-11-22 | 2020-09-30 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| MA52667B1 (fr) * | 2018-03-29 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| CA3118493A1 (en) * | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| TW202039831A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| US20230039976A1 (en) * | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| KR20210111746A (ko) * | 2018-11-08 | 2021-09-13 | 감마델타 테라퓨틱스 리미티드 | 세포를 단리 및 증식하는 방법 |
| JP7710372B2 (ja) * | 2018-12-19 | 2025-07-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用 |
| US20220112557A1 (en) | 2019-01-10 | 2022-04-14 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| US20220257656A1 (en) * | 2019-07-10 | 2022-08-18 | National Cancer Center | Specific marker for identifying t cells specifically attacking cancer cells |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| WO2021030482A1 (en) * | 2019-08-12 | 2021-02-18 | Bellicum Pharmaceuticals, Inc. | Improved formulations for immune cells |
| WO2021032779A1 (en) | 2019-08-19 | 2021-02-25 | Universität Basel | Cell therapy methods |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| JP2022553389A (ja) * | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| EP4090674A4 (en) | 2020-01-14 | 2024-01-24 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US12159700B2 (en) * | 2020-04-22 | 2024-12-03 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2021219990A1 (en) | 2020-04-28 | 2021-11-04 | Achilles Therapeutics Uk Limited | T cell therapy |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| JP7785699B2 (ja) * | 2020-05-29 | 2025-12-15 | シャンハイ ジュンセル セラピューティクス カンパニー リミテッド | 腫瘍浸潤リンパ球の種細胞培地及びその使用 |
| CN111876381A (zh) * | 2020-07-22 | 2020-11-03 | 中美冠科生物技术（太仓）有限公司 | 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用 |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| US20230372397A1 (en) * | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| TW202237824A (zh) | 2020-11-23 | 2022-10-01 | 美商萊爾免疫藥物股份有限公司 | 培養免疫細胞之方法 |
| JP2024501127A (ja) | 2020-11-25 | 2024-01-11 | 上海君賽生物科技有限公司 | 腫瘍浸潤リンパ球培地及びその使用 |
| WO2022111573A1 (zh) | 2020-11-25 | 2022-06-02 | 上海君赛生物科技有限公司 | 增强细胞杀伤的药物组合物及其用途 |
| TW202241468A (zh) * | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者 |
| CA3202483A1 (en) * | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US20240123067A1 (en) * | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| EP4263808A2 (en) * | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP2024500748A (ja) * | 2020-12-18 | 2024-01-10 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
| TW202242085A (zh) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 供自動生產腫瘤浸潤淋巴球的裝置和方法 |
| JPWO2022145490A1 (https=) * | 2021-01-04 | 2022-07-07 | ||
| TW202241508A (zh) * | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| KR20230150833A (ko) | 2021-02-25 | 2023-10-31 | 라이엘 이뮤노파마, 인크. | 세포 배양 방법 |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| WO2022198141A1 (en) * | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| JP2024512978A (ja) * | 2021-03-30 | 2024-03-21 | ネオジェント コーポレーション | 免疫細胞組成物を生成するための方法 |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| CN117203328A (zh) | 2021-04-27 | 2023-12-08 | 武田药品工业株式会社 | 重组抗原呈递细胞 |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| DE102021002748A1 (de) | 2021-05-27 | 2022-12-01 | Zellwerk Gmbh | Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren |
| AU2022292928A1 (en) * | 2021-06-17 | 2024-01-25 | CBio A/S | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use |
| WO2022269250A1 (en) | 2021-06-22 | 2022-12-29 | Achilles Therapeutics Uk Limited | A method for producing antigen-specific t cells |
| US20240365776A1 (en) * | 2021-07-22 | 2024-11-07 | Iovance Biotherapeutics, Inc | Method for cryopreservation of solid tumor fragments |
| US20240342285A1 (en) | 2021-07-28 | 2024-10-17 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| IL311333A (en) | 2021-09-09 | 2024-05-01 | Iovance Biotherapeutics Inc | Processes for generating til products using pd-1 talen knockdown |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2023077034A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| US20250101380A1 (en) * | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| EP4504220A1 (en) | 2022-04-06 | 2025-02-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| EP4522202A1 (en) | 2022-05-10 | 2025-03-19 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
| US20260008990A1 (en) | 2022-07-06 | 2026-01-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4583889A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| US12181192B2 (en) * | 2022-09-16 | 2024-12-31 | Black & Decker, Inc. | Methods and devices for controlling the temperature of a surface |
| CN120239746A (zh) | 2022-09-19 | 2025-07-01 | 图恩疗法股份有限公司 | 用于调节t细胞功能的组合物、系统和方法 |
| WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024112711A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| DE102023002417B3 (de) | 2023-06-15 | 2024-12-05 | Zellwerk Gmbh | Verfahren zur Expansion von Zellen |
| WO2025006811A1 (en) | 2023-06-27 | 2025-01-02 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| AU2024296516A1 (en) | 2023-07-13 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025038289A1 (en) * | 2023-08-17 | 2025-02-20 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Using 12 chemokine signature to select sting agonist and til treatments for solid tumors |
| WO2025047660A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人筑波大学 | 腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞を定量する方法、腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞をスクリーニングする方法、治療用組成物、及びキット |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025256538A1 (zh) * | 2024-06-12 | 2025-12-18 | 北京沙砾生物医药股份有限公司 | 一种细胞产品中检测肿瘤残留的方法 |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
| CN118710478B (zh) * | 2024-08-27 | 2025-01-03 | 福州大学 | 基于改进麻雀搜索算法的地铁突发运营中断客流疏运方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| ITMI20022118A1 (it) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo. |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US8211424B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating malignant melanoma |
| EP1966370B1 (en) | 2005-12-21 | 2013-02-20 | SentoClone International AB | Method for obtaining T-lymphocytes |
| US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| FR2911346B1 (fr) * | 2007-01-12 | 2012-12-07 | Ct Hospitalier Universitaire De Nantes | Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til |
| US7951365B2 (en) | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| US20150320798A1 (en) | 2012-11-27 | 2015-11-12 | The Johns Hopkins University | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity |
| WO2014085437A2 (en) | 2012-11-27 | 2014-06-05 | The Johns Hopkins University | Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8809050B2 (en) | 2009-12-08 | 2014-08-19 | Wilson Wolf Manufacturing | Methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| AU2012324644B2 (en) * | 2011-10-21 | 2014-08-28 | Cell Medica Limited | Device for the aseptic expansion of cells |
| GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| CN102816734A (zh) | 2012-05-09 | 2012-12-12 | 阮润生 | 一种肿瘤抗原特异性t细胞的获取方法 |
| SG11201407226WA (en) | 2012-05-18 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| CN104411819B (zh) | 2012-06-11 | 2019-05-10 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| CN118562610A (zh) | 2013-06-24 | 2024-08-30 | 威尔逊沃夫制造公司 | 用于透气性细胞培养过程的封闭系统装置和方法 |
| JP6616295B2 (ja) * | 2013-07-15 | 2019-12-04 | アメリカ合衆国 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| JP2017511375A (ja) | 2014-03-20 | 2017-04-20 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 養子細胞療法のための腫瘍浸潤リンパ球 |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| AU2015273501B2 (en) | 2014-06-11 | 2021-01-21 | Polybiocept Gmbh | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| EP3155426B1 (en) | 2014-06-13 | 2023-07-19 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
| US9687510B2 (en) | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| US10544392B2 (en) | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
| FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
| WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| CN108463547A (zh) | 2015-10-28 | 2018-08-28 | 生命技术股份公司 | 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群 |
| KR20190037243A (ko) | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
| CN106244538A (zh) | 2016-08-04 | 2016-12-21 | 英普乐孚生物技术(上海)有限公司 | 一种恶性腹水来源的til细胞的分离培养方法 |
| KR102561356B1 (ko) | 2016-09-14 | 2023-08-03 | 애브비 바이오테라퓨틱스 인크. | 항-pd-1 항체 및 이의 용도 |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11401507B2 (en) | 2016-11-17 | 2022-08-02 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| CN106591232A (zh) | 2017-01-04 | 2017-04-26 | 安徽安龙基因医学检验所有限公司 | 一种高效的pd‑1‑cd8+t细胞的培养方法 |
| BR112019013940A2 (pt) | 2017-01-06 | 2020-02-11 | Iovance Biotherapeutics, Inc. | Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica. |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| SG11201908271WA (en) | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US20200224161A1 (en) | 2017-05-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| CN107384867B (zh) | 2017-08-04 | 2020-09-11 | 北京世纪劲得生物技术有限公司 | 一种肿瘤组织til细胞制备方法及专用培养基 |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US12159700B2 (en) | 2020-04-22 | 2024-12-03 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
-
2017
- 2017-06-16 JO JOP/2019/0224A patent/JOP20190224A1/ar unknown
-
2018
- 2018-01-05 MD MDE20200116T patent/MD3601533T2/ro unknown
- 2018-01-05 PE PE2019001976A patent/PE20191841A1/es unknown
- 2018-01-05 JP JP2019553050A patent/JP7169291B2/ja active Active
- 2018-01-05 RS RS20210622A patent/RS61863B1/sr unknown
- 2018-01-05 NZ NZ796152A patent/NZ796152A/en unknown
- 2018-01-05 HR HRP20210677TT patent/HRP20210677T1/hr unknown
- 2018-01-05 RS RS20250109A patent/RS66452B1/sr unknown
- 2018-01-05 EP EP23195819.0A patent/EP4279574A3/en active Pending
- 2018-01-05 CA CA3057975A patent/CA3057975A1/en active Pending
- 2018-01-05 PL PL18709132T patent/PL3601533T3/pl unknown
- 2018-01-05 EP EP20161179.5A patent/EP3730608B1/en active Active
- 2018-01-05 IL IL305198A patent/IL305198A/en unknown
- 2018-01-05 MA MA68856A patent/MA68856B1/fr unknown
- 2018-01-05 FI FIEP20161179.5T patent/FI3730608T3/fi active
- 2018-01-05 SM SM20250027T patent/SMT202500027T1/it unknown
- 2018-01-05 HU HUE18709132A patent/HUE054829T2/hu unknown
- 2018-01-05 DK DK20161179.5T patent/DK3730608T3/da active
- 2018-01-05 AU AU2018243355A patent/AU2018243355B2/en active Active
- 2018-01-05 HU HUE20161276A patent/HUE070256T2/hu unknown
- 2018-01-05 LT LTEP20161179.5T patent/LT3730608T/lt unknown
- 2018-01-05 ES ES20161179T patent/ES3009885T3/es active Active
- 2018-01-05 SM SM20210298T patent/SMT202100298T1/it unknown
- 2018-01-05 PT PT201611795T patent/PT3730608T/pt unknown
- 2018-01-05 SI SI201830278T patent/SI3601533T1/sl unknown
- 2018-01-05 MA MA68598A patent/MA68598B1/fr unknown
- 2018-01-05 HR HRP20250068TT patent/HRP20250068T1/hr unknown
- 2018-01-05 HR HRP20241688TT patent/HRP20241688T1/hr unknown
- 2018-01-05 US US15/863,634 patent/US10894063B2/en active Active
- 2018-01-05 LT LTEP20161276.9T patent/LT3722415T/lt unknown
- 2018-01-05 PL PL20161276.9T patent/PL3722415T3/pl unknown
- 2018-01-05 EP EP18709132.7A patent/EP3601533B1/en active Active
- 2018-01-05 ES ES18709132T patent/ES2874335T3/es active Active
- 2018-01-05 HU HUE20161179A patent/HUE070176T2/hu unknown
- 2018-01-05 KR KR1020247023861A patent/KR20240114787A/ko active Pending
- 2018-01-05 MD MDE20201130T patent/MD3730608T2/ro unknown
- 2018-01-05 SG SG11201908994R patent/SG11201908994RA/en unknown
- 2018-01-05 SI SI201831186T patent/SI3730608T1/sl unknown
- 2018-01-05 EP EP21175134.2A patent/EP3910055A1/en active Pending
- 2018-01-05 MD MDE20201056T patent/MD3722415T2/ro unknown
- 2018-01-05 PT PT201612769T patent/PT3722415T/pt unknown
- 2018-01-05 DK DK20161276.9T patent/DK3722415T3/da active
- 2018-01-05 KR KR1020197031407A patent/KR102686794B1/ko active Active
- 2018-01-05 NZ NZ796142A patent/NZ796142A/en unknown
- 2018-01-05 TW TW107100568A patent/TWI799402B/zh active
- 2018-01-05 PT PT187091327T patent/PT3601533T/pt unknown
- 2018-01-05 RS RS20250044A patent/RS66400B1/sr unknown
- 2018-01-05 CN CN201880035181.8A patent/CN110785486A/zh active Pending
- 2018-01-05 BR BR112019020326A patent/BR112019020326A2/pt unknown
- 2018-01-05 CR CR20190487A patent/CR20190487A/es unknown
- 2018-01-05 ES ES20161276T patent/ES3008832T3/es active Active
- 2018-01-05 EP EP20161276.9A patent/EP3722415B1/en active Active
- 2018-01-05 EP EP20183493.4A patent/EP3766964A1/en active Pending
- 2018-01-05 SM SM20250040T patent/SMT202500040T1/it unknown
- 2018-01-05 MX MX2019011768A patent/MX2019011768A/es unknown
- 2018-01-05 PL PL20161179.5T patent/PL3730608T3/pl unknown
- 2018-01-05 DK DK18709132.7T patent/DK3601533T3/da active
- 2018-01-05 TN TNP/2019/000273A patent/TN2019000273A1/en unknown
- 2018-01-05 SI SI201831203T patent/SI3722415T1/sl unknown
- 2018-01-05 LT LTEP18709132.7T patent/LT3601533T/lt unknown
- 2018-01-05 WO PCT/US2018/012633 patent/WO2018182817A1/en not_active Ceased
- 2018-01-05 UA UAA201910623A patent/UA130566C2/uk unknown
- 2018-01-05 FI FIEP20161276.9T patent/FI3722415T3/fi active
- 2018-01-18 US US15/874,718 patent/US10166257B2/en active Active
- 2018-02-08 US US15/892,311 patent/US10130659B2/en active Active
- 2018-03-29 US US15/940,901 patent/US10918666B2/en active Active
- 2018-06-29 JP JP2020552291A patent/JP7522037B2/ja active Active
- 2018-06-29 US US17/041,305 patent/US12121541B2/en active Active
- 2018-09-19 US US16/136,157 patent/US10420799B2/en active Active
- 2018-09-19 US US16/136,147 patent/US10272113B2/en active Active
- 2018-11-15 US US16/192,707 patent/US10537595B2/en active Active
- 2018-11-27 US US16/201,957 patent/US10398734B2/en active Active
- 2018-11-28 US US16/203,478 patent/US10363273B2/en active Active
- 2018-11-28 US US16/203,467 patent/US10463697B2/en active Active
-
2019
- 2019-05-29 US US16/425,767 patent/US10695372B2/en active Active
- 2019-05-29 US US16/425,778 patent/US10646517B2/en active Active
- 2019-05-29 US US16/425,746 patent/US10639330B2/en active Active
- 2019-09-23 IL IL26954319A patent/IL269543A/en unknown
- 2019-09-27 PH PH12019502247A patent/PH12019502247A1/en unknown
- 2019-09-27 CL CL2019002769A patent/CL2019002769A1/es unknown
- 2019-09-30 MX MX2024002827A patent/MX2024002827A/es unknown
- 2019-10-28 CO CONC2019/0011995A patent/CO2019011995A2/es unknown
- 2019-10-29 EC ECSENADI201977884A patent/ECSP19077884A/es unknown
-
2020
- 2020-01-17 US US16/746,416 patent/US10653723B1/en active Active
- 2020-04-14 US US16/848,442 patent/US10933094B2/en active Active
- 2020-04-14 US US16/848,454 patent/US10946044B2/en active Active
- 2020-04-14 US US16/848,361 patent/US10905718B2/en active Active
- 2020-04-14 US US16/848,426 patent/US10953047B2/en active Active
- 2020-04-14 US US16/848,386 patent/US10953046B2/en active Active
- 2020-04-14 US US16/848,474 patent/US10946045B2/en active Active
- 2020-05-20 US US16/879,711 patent/US10925900B2/en active Active
- 2020-10-22 CL CL2020002737A patent/CL2020002737A1/es unknown
- 2020-12-02 US US17/110,207 patent/US11083752B2/en active Active
- 2020-12-18 US US17/127,795 patent/US11052115B2/en active Active
- 2020-12-18 US US17/127,840 patent/US11052116B2/en active Active
- 2020-12-18 US US17/127,768 patent/US11007225B1/en active Active
- 2020-12-18 US US17/127,790 patent/US11007226B2/en active Active
-
2021
- 2021-01-12 US US17/147,080 patent/US20210128623A1/en active Pending
- 2021-01-12 US US17/147,096 patent/US12226434B2/en active Active
- 2021-01-12 US US17/147,073 patent/US11013770B1/en active Active
- 2021-01-12 US US17/147,412 patent/US20210214685A1/en active Pending
- 2021-01-12 US US17/147,090 patent/US11040070B2/en active Active
- 2021-01-13 US US17/148,475 patent/US11168303B2/en active Active
- 2021-01-13 US US17/148,508 patent/US11168304B2/en active Active
- 2021-05-14 CY CY20211100416T patent/CY1124136T1/el unknown
- 2021-05-20 US US17/326,088 patent/US11202803B1/en active Active
- 2021-07-22 US US17/383,280 patent/US11304979B2/en active Active
- 2021-07-22 US US17/383,276 patent/US11273180B2/en active Active
- 2021-07-22 US US17/383,272 patent/US11202804B2/en active Active
- 2021-07-22 US US17/382,831 patent/US11241456B2/en active Active
- 2021-09-21 US US17/480,596 patent/US11337998B2/en active Active
- 2021-09-21 US US17/480,534 patent/US11291687B2/en active Active
- 2021-09-21 US US17/480,587 patent/US11344579B2/en active Active
- 2021-09-21 US US17/480,525 patent/US11273181B2/en active Active
-
2022
- 2022-07-01 US US17/856,800 patent/US11517592B1/en active Active
- 2022-07-01 US US17/856,793 patent/US20230015649A1/en active Pending
- 2022-07-01 US US17/856,806 patent/US20230133298A1/en active Pending
- 2022-08-03 US US17/817,279 patent/US11541077B2/en active Active
- 2022-08-03 US US17/817,226 patent/US12558375B2/en active Active
- 2022-08-03 US US17/817,217 patent/US20220395533A1/en active Pending
- 2022-08-03 US US17/817,281 patent/US11529372B1/en active Active
- 2022-08-03 US US17/817,273 patent/US20230045899A1/en active Pending
- 2022-08-03 US US17/817,207 patent/US12194061B2/en active Active
- 2022-08-03 US US17/817,276 patent/US20220387498A1/en active Pending
- 2022-08-03 US US17/817,239 patent/US20230012086A1/en active Pending
- 2022-08-03 US US17/817,232 patent/US11998568B2/en active Active
- 2022-10-28 JP JP2022173683A patent/JP7814287B2/ja active Active
- 2022-10-28 JP JP2022173682A patent/JP7772680B2/ja active Active
- 2022-10-28 JP JP2022173684A patent/JP7817138B2/ja active Active
-
2024
- 2024-10-24 JP JP2024187597A patent/JP2025023951A/ja active Pending
- 2024-11-22 US US18/957,327 patent/US12485145B2/en active Active
- 2024-12-17 US US18/984,525 patent/US20250121008A1/en active Pending
- 2024-12-17 US US18/984,595 patent/US20250121009A1/en active Pending
-
2025
- 2025-01-22 AU AU2025200434A patent/AU2025200434A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3730608T3 (fi) | Prosesseja kasvaimeen tunkeutuvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa | |
| FI3775165T3 (fi) | Prosesseja kasvaimiin infiltroituvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa | |
| IL274584B1 (en) | Til expansion from fine needle aspirates and small biopsies | |
| JP2021521846A5 (https=) | ||
| JP2020515257A5 (https=) | ||
| RU2013107155A (ru) | Способы получения кожного трансплантата без культивирования или применения биологических средств | |
| FI3532607T3 (fi) | Kryosäilytettyjen kasvaimiin infiltroituvien lymfosyyttien uudelleen stimulointi | |
| CN104480533A (zh) | 一种胎盘干细胞库的构建方法及胎盘组织复苏方法 | |
| FI3843759T3 (fi) | Tuumoriin filtroituvien lymfosyyttien käyttö anti-PD-1-vasta-aineelle vastustuskykyisten NSCLC-potilaiden hoitoon | |
| CN109161531A (zh) | 一种基于类器官技术个体化肺癌原代细胞培养的方法 | |
| CN105176926A (zh) | 一种体外培养扩增nk细胞的方法 | |
| CN107982285A8 (zh) | 蝉花活性物质及其用于降低眼压的用途 | |
| AR126199A1 (es) | Métodos para aislar linfocitos infiltrantes de tumores y uso de los mismos | |
| Dwek et al. | Synchronization of cell division in microorganisms by Percoll gradients | |
| JPWO2021226061A5 (https=) | ||
| CN103194429A (zh) | 人胃癌肿瘤干细胞株gam-016s的培养建立 | |
| CN103667062A (zh) | 一种樟芝无性孢子低温保藏保护剂及其使用方法 | |
| CN210065793U (zh) | 一种体外模拟循环肿瘤细胞产生装置 | |
| Geng et al. | Multimodal microfluidic platform for controlled culture and analysis of unicellular organisms | |
| AR126198A1 (es) | Procesamiento de linfocitos infiltrantes de tumores | |
| Karyampudi et al. | Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma | |
| Bobik | Optimizing a 3D microfluidic platform for personalized lung cancer drug screening | |
| CN104131046A (zh) | 一种微藻固定化培养的产油方法 | |
| AR117662A1 (es) | Procesos para la producción de linfocitos que infiltran tumores y usos de los mismos en inmunoterapia | |
| PH12018500160A1 (en) | Stem cell culturing method |